upcoming glp-1 drugs Agonists Weight Loss Market Report, 2025-2030 Market Overview: GLP-1 Agonists and

Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development

Science Days are important events in multidistrict litigations

Another network meta-analysis of RCTs, including participants with T2DM, found that GLP-1 RAs decreased the risk of non-fatal MI (Odds Ratio [OR] = 0.92, 95%CI = 0.850.99) when compared to placebo or standard care (Palmer et al., 2021)

2023;doi:10.1056/NEJMoa2301972

Review of the direct and indirect effects of hyperglycemia on the HPA axis in T2DM and the co-occurrence of depression

There is also a pill called Contrave, which combines buproprion and naltrexone and is FDA-approved for weight management, with weight loss of up to 8% after a year